Payment overview · 2025
General Payments
$333.64
18 reported records · 12 companies
Healthcare provider profile · identity verified
Stanley Barnes, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · EVERGREEN, AL · NPI 1518915255
Verified facts
What the public records show
CMS Open Payments records show Stanley Barnes, M.D. received $333.64 in general payments during 2025 across 18 reported records.
Bayer Healthcare Pharmaceuticals Inc. accounted for 17.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Mounjaro, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 202 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 173 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 117 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $58.35 | 17.5% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $37.88 | 11.3% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $35.31 | 10.6% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $33.17 | 9.9% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $30.69 | 9.2% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $29.55 | 8.9% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $23.45 | 7.0% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $20.70 | 6.2% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $20.06 | 6.0% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.23 | 4.6% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $15.03 | 4.5% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $14.22 | 4.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $333.64 | 18 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $58.35 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $37.88 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $35.31 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $33.17 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $30.95 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $29.55 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $23.45 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $20.70 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $20.06 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $20.06 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $15.03 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $14.97 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $14.97 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $14.22 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 81 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 31 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 173 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 43 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
202 | 59 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
31 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
31 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
173 | 29 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
117 | 21 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
81 | 21 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
18 | 18 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 1254 | 168 |
| Amlodipine Besylate | Amlodipine Besylate | 962 | 268 |
| Atorvastatin Calcium | Atorvastatin Calcium | 873 | 245 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 740 | 97 |
| Losartan Potassium | Losartan Potassium | 662 | 192 |
| Potassium Chloride | Potassium Chloride | 615 | 192 |
| Omeprazole | Omeprazole | 606 | 182 |
| Gabapentin | Gabapentin | 598 | 125 |
| Azithromycin | Azithromycin | 593 | 310 |
| Furosemide | Furosemide | 533 | 177 |
| Pantoprazole Sodium | Pantoprazole Sodium | 475 | 132 |
| Cephalexin | Cephalexin | 392 | 214 |
| Clonidine Hcl | Clonidine Hcl | 384 | 104 |
| Meloxicam | Meloxicam | 383 | 132 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 373 | 92 |
| Carvedilol | Carvedilol | 365 | 96 |
| Ibuprofen | Ibuprofen | 336 | 111 |
| Tizanidine Hcl | Tizanidine Hcl | 331 | 65 |
| Tramadol Hcl | Tramadol Hcl | 312 | 83 |
| Metformin Hcl | Metformin Hcl | 309 | 91 |
| Levothyroxine Sodium | Levothyroxine Sodium | 304 | 78 |
| Montelukast Sodium | Montelukast Sodium | 295 | 95 |
| Quetiapine Fumarate | Quetiapine Fumarate | 289 | 54 |
| Metoprolol Succinate | Metoprolol Succinate | 287 | 80 |
| Glipizide | Glipizide | 254 | 72 |
| Allopurinol | Allopurinol | 252 | 74 |
| Hydralazine Hcl | Hydralazine Hcl | 249 | 67 |
| Hydrochlorothiazide | Hydrochlorothiazide | 243 | 72 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 230 | 32 |
| Diclofenac Sodium | Diclofenac Sodium | 216 | 76 |
| Ozempic | Semaglutide | 215 | 42 |
| Tamsulosin Hcl | Tamsulosin Hcl | 215 | 63 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 213 | 67 |
| Fluconazole | Fluconazole | 206 | 97 |
| Fluticasone Propionate | Fluticasone Propionate | 204 | 103 |
| Linzess | Linaclotide | 202 | 59 |
| Metoprolol Tartrate | Metoprolol Tartrate | 197 | 59 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 196 | 106 |
| Mounjaro | Tirzepatide | 173 | 29 |
| Pregabalin | Pregabalin | 172 | 36 |
| Ropinirole Hcl | Ropinirole Hcl | 167 | 56 |
| Sucralfate | Sucralfate | 165 | 53 |
| Amitriptyline Hcl | Amitriptyline Hcl | 161 | 39 |
| Lisinopril | Lisinopril | 160 | 47 |
| Estradiol | Estradiol | 158 | 42 |
| Famotidine | Famotidine | 158 | 55 |
| Amoxicillin | Amoxicillin | 153 | 69 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 151 | 52 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 146 | 50 |
| Escitalopram Oxalate | Escitalopram Oxalate | 142 | 41 |
| Clopidogrel | Clopidogrel Bisulfate | 140 | 41 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 135 | 31 |
| Lorazepam | Lorazepam | 134 | 42 |
| Methylprednisolone | Methylprednisolone | 134 | 77 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 132 | 74 |
| Ondansetron Hcl | Ondansetron Hcl | 122 | 43 |
| Promethazine Hcl | Promethazine Hcl | 122 | 43 |
| Simvastatin | Simvastatin | 117 | 31 |
| Trulicity | Dulaglutide | 117 | 21 |
| Zolpidem Tartrate | Zolpidem Tartrate | 113 | 28 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 111 | 80 |
| Januvia | Sitagliptin Phosphate | 111 | 28 |
| Prednisone | Prednisone | 109 | 55 |
| Valsartan | Valsartan | 104 | 28 |
| Trazodone Hcl | Trazodone Hcl | 100 | 23 |
| Clonazepam | Clonazepam | 94 | 15 |
| Celecoxib | Celecoxib | 88 | 26 |
| Fluoxetine Hcl | Fluoxetine Hcl | 86 | 27 |
| Nifedipine Er | Nifedipine | 86 | 22 |
| Alprazolam | Alprazolam | 84 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 84 | 23 |
| Pioglitazone Hcl | Pioglitazone Hcl | 84 | 23 |
| Eliquis | Apixaban | 81 | 21 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 80 | 31 |
| Naproxen | Naproxen | 76 | 26 |
| Temazepam | Temazepam | 76 | 14 |
| Ketoconazole | Ketoconazole | 75 | 35 |
| Humalog Kwikpen U-100 | Insulin Lispro | 70 | 18 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 68 | 19 |
| Levofloxacin | Levofloxacin | 68 | 44 |
| Meclizine Hcl | Meclizine Hcl | 68 | 30 |
| Metronidazole | Metronidazole | 67 | 45 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 66 | 25 |
| Nystatin | Nystatin | 66 | 40 |
| Atenolol | Atenolol | 64 | 15 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 64 | 17 |
| Methocarbamol | Methocarbamol | 60 | 16 |
| Ibu | Ibuprofen | 59 | 21 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 59 | 12 |
| Diazepam | Diazepam | 58 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 58 | 16 |
| Klor-Con 10 | Potassium Chloride | 57 | 23 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 56 | 14 |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 53 | 18 |
| Mupirocin | Mupirocin | 53 | 35 |
| Colchicine | Colchicine | 52 | 27 |
| Ondansetron Odt | Ondansetron | 52 | 30 |
| Dicyclomine Hcl | Dicyclomine Hcl | 50 | 14 |
| Valacyclovir | Valacyclovir Hcl | 48 | 24 |
| Nitroglycerin | Nitroglycerin | 47 | 15 |
| Labetalol Hcl | Labetalol Hcl | 46 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 46 | 13 |
| Mirtazapine | Mirtazapine | 46 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 46 | suppressed |
| Myrbetriq | Mirabegron | 44 | 12 |
| Vraylar | Cariprazine Hcl | 43 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 42 | 13 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 42 | 11 |
| Spironolactone | Spironolactone | 42 | 14 |
| Topiramate | Topiramate | 42 | 13 |
| Glipizide Er | Glipizide | 41 | 14 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 39 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 38 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 37 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 37 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 37 | suppressed |
| Penicillin V Potassium | Penicillin V Potassium | 35 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 34 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 34 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 33 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 33 | 11 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 33 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 32 | suppressed |
| Metolazone | Metolazone | 32 | 12 |
| Farxiga | Dapagliflozin Propanediol | 31 | suppressed |
| Jardiance | Empagliflozin | 31 | 11 |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 31 | 15 |
| Gemtesa | Vibegron | 30 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 30 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 28 | suppressed |
| Terconazole | Terconazole | 28 | 11 |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 27 | suppressed |
| Irbesartan | Irbesartan | 27 | suppressed |
| Levetiracetam | Levetiracetam | 27 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 27 | suppressed |
| Baclofen | Baclofen | 26 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 26 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 26 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 25 | suppressed |
| Finasteride | Finasteride | 25 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 25 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 25 | 11 |
| Bupropion Xl | Bupropion Hcl | 24 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 24 | 17 |
| Olanzapine | Olanzapine | 24 | suppressed |
| Ranolazine Er | Ranolazine | 24 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 24 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 24 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 23 | suppressed |
| Verapamil Er | Verapamil Hcl | 23 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 22 | 11 |
| Benazepril Hcl | Benazepril Hcl | 22 | suppressed |
| Bumetanide | Bumetanide | 22 | suppressed |
| Dexamethasone | Dexamethasone | 22 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 22 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 22 | suppressed |
| Naloxone Hcl | Naloxone Hcl | 22 | 22 |
| Fenofibrate | Fenofibrate | 21 | suppressed |
| Indomethacin | Indomethacin | 21 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 21 | 18 |
| Novolog Flexpen | Insulin Aspart | 21 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 21 | suppressed |
| Telmisartan | Telmisartan | 21 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 20 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 20 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Ultra-Fine Original Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 19 | suppressed |
| Aripiprazole | Aripiprazole | 19 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 19 | 16 |
| Theophylline Er | Theophylline Anhydrous | 19 | suppressed |
| Tobramycin | Tobramycin | 19 | 14 |
| Levemir Flexpen | Insulin Detemir | 18 | suppressed |
| Lovastatin | Lovastatin | 18 | suppressed |
| Minoxidil | Minoxidil | 18 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 18 | 18 |
| Premarin | Estrogens, Conjugated | 18 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 17 | suppressed |
| Glimepiride | Glimepiride | 17 | suppressed |
| Hydrocortisone | Hydrocortisone | 17 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 16 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 16 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 16 | suppressed |
| Estradiol-Norethindrone Acetat | Estradiol/Norethindrone Acet | 15 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 15 | suppressed |
| Restasis | Cyclosporine | 15 | suppressed |
| Tobramycin-Dexamethasone | Tobramycin/Dexamethasone | 15 | 13 |
| Diltiazem 24hr Er | Diltiazem Hcl | 14 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 14 | suppressed |
| Entresto | Sacubitril/Valsartan | 14 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 14 | suppressed |
| Primidone | Primidone | 14 | suppressed |
| Clonidine | Clonidine | 13 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 13 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 13 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 12 | 11 |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 12 | 12 |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 12 | suppressed |
| Isosorbide Mononitrate | Isosorbide Mononitrate | 12 | suppressed |
| Lactulose | Lactulose | 12 | suppressed |
| Phenobarbital | Phenobarbital | 12 | suppressed |
| Risperidone | Risperidone | 12 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 12 | suppressed |
| Xarelto | Rivaroxaban | 12 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 11 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 11 | suppressed |
| Digoxin | Digoxin | 11 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 11 | suppressed |
| Lamotrigine | Lamotrigine | 11 | suppressed |
| Permethrin | Permethrin | 11 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
| Ramipril | Ramipril | 11 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $333.64 · 18 records | Bayer Healthcare Pharmaceuticals Inc. | BREZTRI, CAPLYTA, Cologuard Collection Kit, ELIQUIS, IBSRELA, JARDIANCE, Kerendia, MOUNJARO, NURTEC ODT, TRELEGY ELLIPTA, TRINTELLIX, VRAYLAR, ZEPBOUND, ZORYVE | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error